摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

Komaroviquinone

中文名称
——
中文别名
——
英文名称
Komaroviquinone
英文别名
(1S,9S,11S)-9-hydroxy-5-methoxy-12,12-dimethyl-6-propan-2-yl-16-oxatetracyclo[7.6.1.01,11.03,8]hexadeca-3(8),5-diene-4,7-dione
Komaroviquinone化学式
CAS
——
化学式
C21H28O5
mdl
——
分子量
360.45
InChiKey
DUWHKUPNNGPNFK-ZEWGMFERSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.8
  • 重原子数:
    26
  • 可旋转键数:
    2
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.71
  • 拓扑面积:
    72.8
  • 氢给体数:
    1
  • 氢受体数:
    5

反应信息

  • 作为反应物:
    描述:
    Komaroviquinone环己烷 为溶剂, 反应 1.0h, 以90%的产率得到komarovispirone
    参考文献:
    名称:
    Total Synthesis of (+)-Komarovispirone
    摘要:
    (+)-Komaroviquinone 在光照下重新排列为 (+)- Komarovispirone。本文对这种异构化的机理进行了阐述。
    DOI:
    10.1021/ol7017449
  • 作为产物:
    参考文献:
    名称:
    Total Synthesis of (+)-Komaroviquinone
    摘要:
    化合物(+)小檗碱素甲素酮(1)通过烯酮8在十二步反应中成功合成。该研究开发了三条全新的合成路线来制备关键中间体二烯酮11。值得注意的是,这两个关键步骤分别实现了区域选择性溴水合反应以氧化C(7),以及区域和立体选择性溴水合反应以引入β-C(10)酒精结构,显著提升了合成效率和产物质量。
    DOI:
    10.3987/com-07-s(u)37
点击查看最新优质反应信息

文献信息

  • [EN] LYMPHATIC SYSTEM-DIRECTING LIPID PRODRUGS<br/>[FR] PROMÉDICAMENTS LIPIDIQUES ORIENTANT VERS LE SYSTÈME LYMPHATIQUE
    申请人:ARIYA THERAPEUTICS INC
    公开号:WO2019046491A1
    公开(公告)日:2019-03-07
    The present invention provides lymphatic system-directing lipid prodrugs, pharmaceutical compositions thereof, methods of producing such prodrugs and compositions, as well as methods of improving the bioavailability or other properties of a therapeutic agent that comprises part of the lipid prodrug. The present invention also provides methods of treating a disease, disorder, or condition such as those disclosed herein, comprising administering to a patient in need thereof a provided lipid prodrug or a pharmaceutical composition thereof.
    本发明提供了淋巴系统定向脂质前药,其制药组合物,制备这种前药和组合物的方法,以及改善作为脂质前药一部分的治疗剂的生物利用度或其他性质的方法。本发明还提供了治疗疾病、紊乱或症状的方法,包括向需要的患者施用所提供的脂质前药或其制药组合物。
  • Total Synthesis of (±)-Brussonol and (±)-Komaroviquinone via a Regioselective Cross-Electrophile Coupling of Aryl Bromides and Epoxides
    作者:Anees Ahmad、Antonio C. B. Burtoloso
    DOI:10.1021/acs.orglett.9b02221
    日期:2019.8.2
    The short and stereoselective syntheses of diterpenes (±)-brussonol and (±)-komaroviquinone, via a Ni-catalyzed epoxide ring-opening approach in the presence of aryl halides, is described. Key steps involve the effective preparation of a challenging hemiacetal intermediate in a single operation, followed by a highly efficient BF3·OEt2-catalyzed Friedel–Craft alkylation, to construct the tricyclic skeleton
    描述了在芳基卤化物存在下,通过Ni催化的环氧基开环方法,二萜(±)-布鲁索醇和(±)-komroviquinone的短和立体选择性合成。关键步骤包括在一次操作中有效制备具有挑战性的半缩醛中间体,然后进行高效的BF 3 ·OEt 2催化的Friedel-Craft烷基化反应,以构建这些二萜的三环骨架。合成方法可能为合成含有冰松烷图案的几种天然产物提供一条统一的途径。
  • Collective Syntheses of Icetexane Natural Products Based on Biogenetic Hypotheses
    作者:Christophe Thommen、Markus Neuburger、Karl Gademann
    DOI:10.1002/chem.201603932
    日期:2017.1.1
    divergent synthesis of 10 icetexane natural products based on a proposed biogenetic cationic ring expansion of a reduced carnosic acid derivative is described. Of these icetexanes, (+)‐salvicanol, ()‐cyclocoulterone, ()‐coulterone, ()‐obtusinone D, and ()‐obtusinone E have been synthesized for the first time. In addition, the hypothesis for the non‐enzymatic biogenesis of benzo[1,3]dioxole natural products
    描述了基于还原的肌酸生物的拟议的生物遗传阳离子环扩链的10种冰烷天然产物的发散性合成。在这些冰tex烷中,首次合成了(+)-山杨醇,(-)-环香豆酮,(-)-香豆酮,(-)-奥布他酮D和(-)-奥布他酮E。另外,已经通过实验研究了苯并[1,3]二恶唑天然产物的非酶促生物发生假说。还提供了有关亚甲二氧基单元非生物形成的其他实验证据,因为醌(+)-komroviquinone的光解导致含[1,3]二恶唑天然产物(-)-环库尔酮和(+)-的形成。科马罗匹螺酮。
  • Stereoselective Syntheses of (±)-Komaroviquinone and (±)-Faveline Methyl Ether through Intramolecular Heck Reaction
    作者:Sujaya Sengupta、Michael G. B. Drew、Ranjan Mukhopadhyay、Basudeb Achari、Asish Kr. Banerjee
    DOI:10.1021/jo051082i
    日期:2005.9.1
    An efficient, flexible, and stereoselective convergent route for constructing the trans-10-hydroxy-1,1-dimethyloctahydrodibenzo[a,d]cyclohepten-7-ones (5a−c) was achieved via intramolecular Heck reaction. This strategy has been successfully implemented for the syntheses of (±)-komaroviquinone (3) through (±)-coulterone dimethyl ether (5c) and (±)-faveline methyl ether (1a).
    通过分子内Heck反应实现了构建反式-10-羟基-1,1-二甲基八氢二苯并[ a,d ]环庚-7-酮(5a - c)的有效,灵活和立体选择性的聚合途径。该策略已成功实施,用于通过(±)-香豆酮甲醚(5c)和(±)-faveline甲醚(1a)合成(±)-科马罗维醌(3)。
  • Synthesis and biological evaluation of the natural product komaroviquinone and related compounds aiming at a potential therapeutic lead compound for high-risk multiple myeloma
    作者:Yutaka Suto、Mariko Sato、Kota Fujimori、Shotaro Kitabatake、Mikio Okayama、Daiju Ichikawa、Maiko Matsushita、Noriyuki Yamagiwa、Genji Iwasaki、Fumiyuki Kiuchi、Yutaka Hattori
    DOI:10.1016/j.bmcl.2017.08.054
    日期:2017.10
    asymmetric total synthesis of komaroviquinone, which is a natural product from the plant Dracocephalum komarovi. Similar to several leading antitumor agents that have been developed from natural compounds, we describe the antitumor activity and cytotoxicity of komaroviquinone and related compounds in bone marrow cells. Our data suggested that komaroviquinone-related agents have potential as starting compounds
    随着诸如蛋白酶抑制剂沙利度胺生物,组蛋白脱乙酰基酶抑制剂抗体药物等新药的出现,治疗多发性骨髓瘤(MM)的替代方法越来越多。然而,对于新药难治的高危MM病例仍然存在,迫切需要进一步优化化疗药物。 我们已经实现了komaroviquinone的不对称全合成,而komaroviquinone是植物Dracocephalum komarovi的天然产物。与从天然化合物开发出来的几种领先的抗肿瘤药相似,我们描述了考马罗维醌和相关化合物在骨髓细胞中的抗肿瘤活性和细胞毒性。我们的数据表明,与科马罗维醌有关的药物有可能作为抗癌药物开发的起始化合物。
查看更多

表征谱图

  • 氢谱
    1HNMR
  • 质谱
    MS
  • 碳谱
    13CNMR
  • 红外
    IR
  • 拉曼
    Raman
查看更多图谱数据,请前往“摩熵化学”平台
查看更多图谱数据,请前往“摩熵化学”平台
cnmr
查看更多图谱数据,请前往“摩熵化学”平台
查看更多图谱数据,请前往“摩熵化学”平台
  • 峰位数据
  • 峰位匹配
  • 表征信息
Shift(ppm)
Intensity
查看更多图谱数据,请前往“摩熵化学”平台
Assign
Shift(ppm)
查看更多图谱数据,请前往“摩熵化学”平台
测试频率
样品用量
溶剂
溶剂用量
查看更多图谱数据,请前往“摩熵化学”平台

同类化合物

萘啶霉素 苯酚,4-(4-吗啉基磺酰)- 焦曲二醇 核丛青霉素 异色酮VI [(7R)-7-甲基-6,8-二氧代-3-[(E)-丙-1-烯基]异苯并吡喃-7-基]2,4-二羟基-6-甲基苯甲酸酯 (E,E,E)-(-)-7-(乙酰氧基)-3-(1,3,5-庚三烯基)-7-甲基-6H-2-苯并吡喃-6,8(7H)-二酮 (7S,8S)-5-氯-3-[(1E,3E)-3,5-二甲基庚-1,3-二烯基]-7,8-二羟基-7-甲基-8H-异苯并吡喃-6-酮 (7R,8R)-5-氯-3-[(1E,3E,5S)-3,5-二甲基庚-1,3-二烯-1-基]-7,8-二羟基-7-甲基-7,8-二氢-6H-异色烯-6-酮 Acetic acid 2-((11S,13S,16S,17R)-11,17-dihydroxy-13,16-dimethyl-3-oxo-10,11,12,13,14,15,16,17-octahydro-3H-cyclopenta[a]phenanthren-17-yl)-2-oxo-ethyl ester (+/-)-5-Chlorrotioramin Acetic acid 3-((1E,3E,5E)-hepta-1,3,5-trienyl)-7-methyl-6,8-dioxo-2,6,7,8-tetrahydro-isoquinolin-7-yl ester Acetic acid 6-acetoxy-7-methyl-8-oxo-3-((E)-propenyl)-3,4,5,6,7,8-hexahydro-1H-isochromen-7-yl ester 3-((1E,3E,5E)-Hepta-1,3,5-trienyl)-7-hydroxy-2,7-dimethyl-2H-isoquinoline-6,8-dione Deacetylwortmin Acetic acid 3-((1E,3E,5E)-hepta-1,3,5-trienyl)-2,7-dimethyl-6,8-dioxo-2,6,7,8-tetrahydro-isoquinolin-7-yl ester 7,8-Dihydro-7,8-dihydroxy-3,5,7-trimethyl-2-benzopyran-6-on (7R,8S)-7,8-Dihydroxy-3,7-dimethyl-5-((E)-3-oxo-but-1-enyl)-7,8-dihydro-isochromen-6-one 5-bromo-3-(3-methoxyphenyl)-7-methyl-6,8-dioxo-7,8-dihydro-6H-isochromen-7-yl acetate (7R,8S)-5-Bromo-7,8-dihydroxy-3,7-dimethyl-7,8-dihydro-isochromen-6-one 3-(3-chlorophenyl)-7-hydroxy-7-methyl-6H-isochromene-6,8(7H)-dione t-Butyl-6-dimethyl-2,2-carbethoxy-5-dihydro-2,3-pyron-4 ethyl 2-[3-[(1E,3E,5S)-3,5-dimethylhepta-1,3-dienyl]-7-hydroxy-7-methyl-6-oxoisochromen-8-ylidene]acetate [(7S)-3-(3-acetyloxypropyl)-5-chloro-7-methyl-6,8-dioxoisochromen-7-yl] butanoate [5-Bromo-3-(4-methoxyphenyl)-7-methyl-6,8-dioxoisochromen-7-yl] 3-phenylpropanoate 5-cyano-2-methyl-4-oxo-5-(3-oxo-butyl)-4,5-dihydro-pyrrole-3-carboxylic acid ethyl ester 1-O-methyl 4-O-[7-methyl-3-[3-[(2-methylpropan-2-yl)oxycarbonylamino]propyl]-6,8-dioxoisochromen-7-yl] butanedioate Lunatsaeure-A-methylester (2S,4S)-2,4-Dimethyl-hexanoic acid (R)-3-((E)-2-methoxycarbonyl-vinyl)-7-methyl-6,8-dioxo-2,6,7,8-tetrahydro-isoquinolin-7-yl ester (2S,4S)-2,4-Dimethyl-hexanoic acid (R)-3-(2-methoxycarbonyl-ethyl)-7-methyl-6,8-dioxo-7,8-dihydro-6H-isochromen-7-yl ester [3-((R)-7-Hydroxy-7-methyl-6,8-dioxo-7,8-dihydro-6H-isochromen-3-yl)-propyl]-carbamic acid tert-butyl ester ethyl 2-[5-bromo-3-[(1E,3E,5S)-3,5-dimethylhepta-1,3-dienyl]-7-hydroxy-7-methyl-6-oxoisochromen-8-ylidene]acetate (E)-3-((7R,8R)-7,8-Dihydroxy-7-methyl-6-oxo-7,8-dihydro-6H-isochromen-3-yl)-acrylic acid methyl ester (R)-5-chloro-3-((S,1E,3E)-3,5-dimethylhepta-1,3-dien-1-yl)-7-methyl-6,8-dioxo-2-phenyl-2,6,7,8-tetrahydroisoquinolin-7-yl acetate cazisochromene methyl 2-[(1R,3R)-7-bromo-1-hydroxy-1-methyl-5,8-dioxo-3,4-dihydroisochromen-3-yl]acetate (7R,8S,7′R,8′S)-5-[(7′,8′-dihydroxy-3′,7′-dimethyl-6′-oxo-7′,8′-dihydro-6′H-isochromen-5′-yl)methyl]-7,8-dihydroxy-3,7-dimethyl-7,8-dihydro-6H-isochromen-6-one (5-Bromo-7-methyl-6,8-dioxo-3-phenylisochromen-7-yl) acetate Bis-boc-Mitorubrinic acid t-butyl ester methyl 4-(5-bromo-7-hydroxy-7-methyl-6,8-dioxo-7,8-dihydro-6H-isochromen-3-yl)butanoate (Z)-2-((2-(4-bromo-3-methyl-5-oxofuran-2(5H)-ylidene)ethoxy)methyl)-5-oxo-5,6-dihydro-2H-pyran-2-yl acetate 3-<(1E)-1,3-dimethylpent-1-enyl>-8,9-dihydro-7-methoxy-9-oxo-8-(2-oxopropyl)-1H-naphtho<2,3-c>pyran-8,10-diyl diacetate Dothideomynone C 5-bromo-3-(4-methoxy-4-oxobutyl)-7-methyl-6,8-dioxo-7,8-dihydro-6H-isochromen-7-yl cyclopentanecarboxylate (R)-7-acetoxy-2-amino-5-chloro-3-((S)-3,5-dimethyl-hepta-1,3t-dien-t-yl)-7-methyl-2H-isoquinoline-6,8-dione